Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 123-128

  Tabata, Kenji ^a   Katashima, Masataka ^a   Kawamura, Akio ^a   Kagayama, Akira ^a   Kohno, Shigeru ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Metabolites; Micafungin; Patients; Pharmacokinetics pharmacodynamics

Indexed keywords

DRUG METABOLITE; MICAFUNGIN;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MYCOSIS; TREATMENT OUTCOME;

EID: 33746699015     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191129     Document Type: Article

References (14)

1. Denning D.W. (2003): Echinocandin antifungal drugs. Lancet, 362, 1142-1151.
2. Fromtling R.A. (2002): Micafungin sodium (FK-463). Drugs Today, 38, 245-257.
3. Peggy L. (2004): Micafungin. Ann. Pharmacother., 38, 1707-1721.
4. Zaas A.K., Steinbach W.J. (2005): Micafungin: US perspective. Expert. Rev. Anti. Infect. Ther., 3, 183-190.
5. Comely O.A., Schmits K., Aisenbrey S. (2002): The first echinocandin: caspofungin. Mycosis. 45 (suppl. 3):56-60.
6. Letscher B.V., Herbrecht R. (2003): Caspofungin: the first representative of a new antifungal class. Antimicrob. Agents Chemother., 51, 513-521.
7. Helen W.B., Andreas H.G., Christine C.C., Thomas J.W. (2004): Newer systemic antifungal agents - pharmacokinetics, safety and efficacy. Drugs, 64, 1992-2020.
8. Azuma J., Nakahara K., Kagayama A., Kajiho T., Kawamura A., Suematsu H., Mukai T. (2002): Phase I study of micafungin. Jpn. J. Chemother., 50(suppl. 1), 104-147.
9. Azuma J., Nakahara K., Kagayama A., Okuma T., Kawamura A. and Mukai T. (2002): Pharmacokinetic study of micafungin. Jpn. J. Chemother., 50(suppl. 1), 155-184.
10. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., Niki Y., Ikemoto H. (2004): A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scanj. J. Infect. Dis., 36, 372-379.
11. Ikeda F., Otomo K., Wakai Y., Mutoh S. (2002): Antifungal activities of the M1, M2 and M5 metabolites of micafungin. Jpn. J. Chemother., 50 (suppl. 1), 54-57.
12. Yamato Y., Kaneko H., Tanimoto K., Katashima M., Ishibashi K., Kawamura A., Terakawa M., Kagayama A. (2002): Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn. J. Chemother., 50 (suppl. 1), 68-73.
13. Azuma J., Nakahara K., Kagayama A., Kajiho T., Kawamura A. Suematsu H., Mukai T. (2002): Pharmacokinetics study of micafungin in elderly subjects. Jpn. J. Chemother., 50 (suppl. 1), 148-154.
14. Kaneko H., Yamato Y., Teramura Y., Fujiwara T., Suzuki A., Kawamura A., Terakawa M., Kagayama A.: Metabolism of micafungin in rats and dogs. Jpn. J. Chemother., 50 (suppl. 1), 88-93.